The 4-anilinoquinazoline based reversible EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have been demonstrated effective in treating advanced NSCLC with EGFR mutants [4–8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.